New combo shrinks liver tumors in hard-to-treat colorectal cancer
NCT ID NCT07024537
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a treatment for people with colorectal cancer that spread to the liver and had not responded to at least two prior therapies. The treatment combined a strong chemotherapy cocktail delivered directly to the liver (FOLFOXIRI via hepatic arterial infusion) with an oral targeted drug called fuquintinib. The goal was to see how many patients' tumors shrank significantly. 44 patients took part in this single-arm phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China